M Pharmaceutical Inc.

M Pharmaceutical Inc.

July 16, 2015 09:00 ET

M Pharmaceutical Inc. Rebrands Itself to Better Reflect Growing Family of Biomedical Technologies

New Corporate Identity Will Enhance Understanding of Biomedical Technologies Designed to Improve the Health of Those Affected by Obesity and Diabetes

VANCOUVER, BRITISH COLUMBIA--(Marketwired - July 16, 2015) - M Pharmaceutical Inc. (CSE:MQ)(OTCQB:MPHMF)(FRANKFURT:T3F1) (the "Company"), a Canadian company committed to developing and commercializing innovative biomedical technologies that improve the health and quality of life for people affected by obesity and diabetes, is formally announcing its corporate rebranding. Under the mantra "Better Health. Better Life." M Pharmaceutical, Inc. today unveiled the building blocks of its new corporate and product identity plan.

The rebranding is designed to provide greater understanding of the company's emerging family of biomedical technologies. Joining the eMosquito Wearable Blood Monitor will be Trimeo Weight Loss Capsules and the Trimtec Gastric Stimulation System.

"Our new approach and communications platform will help us in our pursuit of excellence in the biomedical technologies that we believe will make a palpable difference in the lives of people living with obesity and diabetes," said Dr. Martin Mintchev of Calgary, President & Chief Executive Officer of M Pharmaceutical, Inc. "The rebranding simplifies the comprehensive vision of M Pharmaceutical, Inc. and crystalizes the story behind the eMosquito. In introducing Trimeo and Trimtec to our family, it represents an exciting new chapter in the growth and development of our company."

M Pharmaceutical, Inc. is using the new corporate identity to reinforce its commitment to developing and commercializing its innovative biomedical technologies which offer the end user realistic solutions based on the principles of reduced invasiveness and enhanced effectiveness.

The mantra "Better Health. Better Life." will be prominent in the rebranding, as will the connectivity and synergies between the eMosquito Wearable Blood Monitor, Trimeo Weight Loss Capsules and Trimtec Gastric Stimulation System.

The family of biomedical products are linked by the common "M" embedded in a stylized Circle of Life. The corporate brand mark and all product marks will share the common M in a colour-coded protocol that will be consistently applied across all communications platforms.

"The Circle of Life that will represent M Pharmaceutical, Inc. going forward is designed to remind all of us and our stakeholders of the importance of collaboration in the execution of our business plan and invoke the targeted focus we have around providing integrated solutions for the people who need our biomedical technologies most," added Dr. Mintchev.

"We commissioned the rebranding because we felt it was the best way to bring our family of biomedical technologies together under one roof," said George Tsafalas, a member of the Board of Directors of M Pharmaceutical, Inc. "Based on the quality of people who have joined with Dr. Mintchev on our leadership team, our Board and our Advisory group, and given the progress the team has made on all fronts, we believed it was the right time to usher in our new look and feel."

The "Better Health. Better Life." mantra and Circle of Life corporate identity is now online at www.m-pharma.ca.

About M Pharmaceutical Inc.

M Pharmaceutical Inc. is committed to developing and commercializing innovative biomedical technologies that improve the health and quality of life of people affected by obesity and diabetes. The Company currently has the exclusive rights to a family of biomedical technologies including (i) the eMosquito, for automatic and autonomous monitoring of blood glucose by diabetics; (ii) temporary controllable pseudobezoars, an innovative method for non-invasive dynamic gastric volume reduction for weight loss that has been recently tested in blind, placebo-controlled human studies; and (iii) gastrointestinal neurostimulators, using a laparoscopically-implantable technique for the treatment of obesity without permanent anatomical modification of the stomach. Commercial development of eMosquito, Trimeo and Trimtec biomedical technologies will require successful coordination and execution of a wide variety of technology disciplines.

Forward-Looking Statements:

This news release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the commercialization of the rights to the eMosquito, Trimeo and Trimtec biomedical technologies. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents which can be found under the Company's profile on www.sedar.com and such factors as the Company failing to complete the commercialization of the eMosquito, Trimeo and Trimtec biomedical technologies.

Contact Information